CBA-0710

N/A

Report date: 2025/01/26 17:48:42

Base Information

Drug NameCBA-0710

Drug Alias Nameanti-c-Met/PD-L1 bispecific antibody (Sorrento Therapeutics)dual PD-L1 checkpoint inhibitor/anti-c-Met (Sorrento Therapeutics)CBA-0710

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionHepatocyte growth factor receptor modulatorsProgrammed death-ligand 1 blockers

TargetsProgrammed death-ligand 1Hepatocyte growth factor receptor

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSorrento Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesSorrento Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A